Class II · Moderate risk
Kali Sulphuricum 3X
Out-of-specification test results obtained for identification testing based on HPTLC analysis.
Class II drug recalls - moderate risk
Class II means the product may cause temporary or medically reversible harm, and serious harm is unlikely. It is by far the largest recall class - most potency, dissolution and labeling problems land here.
14,535 recalls, newest first.
Class II · Moderate risk
La Core LCL-2-0191 Blend
Out-of-specification test results obtained for identification testing based on HPTLC analysis.
Class II · Moderate risk
Viola Odorata 4X
Out-of-specification test results obtained for identification testing based on HPTLC analysis.
Class II · Moderate risk
Verbena Officinalis 6X
Out-of-specification test results obtained for identification testing based on HPTLC analysis.
Class II · Moderate risk
Quebracho 4C
Out-of-specification test results obtained for identification testing based on HPTLC analysis.
Class II · Moderate risk
Humulus 6X
Out-of-specification test results obtained for identification testing based on HPTLC analysis.
Class II · Moderate risk
Cistus Canadensis 6X
Out-of-specification test results obtained for identification testing based on HPTLC analysis.
Class II · Moderate risk
Cinnamomum 6X
Out-of-specification test results obtained for identification testing based on HPTLC analysis.
Class II · Moderate risk
Althaea Officinalis 4X
Out-of-specification test results obtained for identification testing based on HPTLC analysis.
Class II · Moderate risk
Cedar Fever Drops
Out-of-specification test results obtained for identification testing based on HPTLC analysis.
Class II · Moderate risk
Haloderm Homeopathic Blend
Out-of-specification test results obtained for identification testing based on HPTLC analysis.
Class II · Moderate risk
Yeast Guard Blend
Out-of-specification test results obtained for identification testing based on HPTLC analysis.
Class II · Moderate risk
Occular Allergy Blend 87% Alcohol
Out-of-specification test results obtained for identification testing based on HPTLC analysis.
Class II · Moderate risk
ZTE-105 Formula Gentle Detoxing. Contents 1000 mL
Out-of-specification test results obtained for identification testing based on HPTLC analysis.
Class II · Moderate risk
Aconitum nap Fear* 87% Alcohol HPUS: 5X
Out-of-specification test results obtained for identification testing based on HPTLC analysis.
Class II · Moderate risk
Oxycodone Hydrochloride Tablets
Presence of Foreign Tablets/Capsules; A single foreign tablet Hydrochlorothiazide/Lisinopril 25/20 was found in one bottle
Class II · Moderate risk
Trulicity (dulaglutide)
Labeling: Label error on declared strength - autoinjector devices labeled as 0.75 mg / 0.5 mL actually contain 1.5 mg / 0.5 mL of product.
Class II · Moderate risk
Spironolactone Ophthalmic Solution 0.005 mg/mL
Lack of Assurance of Sterility
Class II · Moderate risk
Carvedilol 25 mg
A 500 count bottle of Carvedilol 25 mg tablets contained two Paroxetine Tablets, 40 mg. Product was repackaged into 180 count bottles.
Class II · Moderate risk
Chantix (varenicline)
CGMP Deviations: Presence of the N-nitroso-varenicline impurity above FDA s acceptable interim acceptable intake limit
Class II · Moderate risk
Chantix (varenicline)
CGMP Deviations: Presence of the N-nitroso-varenicline impurity above FDA s acceptable interim acceptable intake limit
Class II · Moderate risk
Chantix (varenicline)
CGMP Deviations: Presence of the N-nitroso-varenicline impurity above FDA s acceptable interim acceptable intake limit
Class II · Moderate risk
Chantix (varenicline)
CGMP Deviations: Presence of the N-nitroso-varenicline impurity above FDA s acceptable interim acceptable intake limit
Class II · Moderate risk
Betamethasone Dipropionate Lotion USP
Failed impurities/degradation specification: Out of Specification for an unknown impurity observed in topical product.
Class II · Moderate risk
Sodium Phenylbutyrate POWDER
Failed Impurities Specifications: Out of Specification impurity results obtained during routine testing.